Next report date
Report period
Q1 2024
EPS estimate
−0.10EUR
Revenue estimate
179.34 MEUR
−2.904EUR
−238.55 MEUR
682.41 MEUR
86.02 M
About Myriad Genetics, Inc.
Sector
Industry
CEO
Paul J. Diaz
Website
Headquarters
Salt Lake City
Employees (FY)
2.7 K
Founded
1991
FIGI
BBG000KNHG93
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange MYRIAD GENETICS INC. stocks are traded under the ticker MYD.
MYRIAD GENETICS INC. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
MYD earnings for the last quarter are −0.03 EUR per share, whereas the estimation was −0.07 EUR resulting in a 60.29% surprise. The estimated earnings for the next quarter are 0.01 EUR per share. See more details about MYRIAD GENETICS INC. earnings.
MYRIAD GENETICS INC. revenue for the last quarter amounts to 181.54 M EUR despite the estimated figure of 172.47 M EUR. In the next quarter revenue is expected to reach 176.49 M EUR.
Yes, you can track MYRIAD GENETICS INC. financials in yearly and quarterly reports right on TradingView.
MYD net income for the last quarter is −28.27 M EUR, while the quarter before that showed −57.99 M EUR of net income which accounts for 51.25% change. Track more MYRIAD GENETICS INC. financial stats to get the full picture.
No, MYD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MYD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MYRIAD GENETICS INC. stock right from TradingView charts — choose your broker and connect to your account.
As of May 1, 2024, the company has 2.70 K employees. See our rating of the largest employees — is MYRIAD GENETICS INC. on this list?
We've gathered analysts' opinions on MYRIAD GENETICS INC. future price: according to them, MYD price has a max estimate of 29.05 EUR and a min estimate of 11.24 EUR. Read a more detailed MYRIAD GENETICS INC. forecast: see what analysts think of MYRIAD GENETICS INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MYRIAD GENETICS INC. EBITDA is −68.04 M EUR, and current EBITDA margin is −9.48%. See more stats in MYRIAD GENETICS INC. financial statements.